ArticleProceedings of the National Academy of Sciences of the United States of America2008
The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Review
- Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on "Pseudovirus-like" Nanoparticles.ACS nano · 2022Article
- Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome.Frontiers in immunology · 2022Article
- Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition.International journal of molecular sciences · 2020Article
- The prevalence of antibodies against the HLA-DRB3 protein in kidney transplantation and the correlation with HLA expression.PloS one · 2018Article
- Using DR52c/NiToxicology and applied pharmacology · 2017Article
- Major histocompatibility complex variation and the evolution of resistance to amphibian chytridiomycosis.Immunogenetics · 2017Review
- Next generation sequencing reveals the association of DRB3*02:02 with type 1 diabetes.Diabetes · 2013Article
- Structural basis of metal hypersensitivity.Immunologic research · 2013Review
- Linkers in the structural biology of protein-protein interactions.Protein science : a publication of the Protein Society · 2013Review
- T-cell receptor (TCR) interaction with peptides that mimic nickel offers insight into nickel contact allergy.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- The conundrum of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated hematopoietic SCT.Bone marrow transplantation · 2011Article
- Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- An automated framework for understanding structural variations in the binding grooves of MHC class II molecules.BMC bioinformatics · 2010Article
- Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.European journal of immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Class II major histocompatibility complex (MHCII) molecules present antigens to CD4(+) T cells. In addition to the most commonly studied human MHCII isotype, HLA-DR, whose beta chain is encoded by the HLA-DRB1 locus, several other isotypes that use the same alpha chain but have beta chains encoded by other genes. These other DR molecules also are expressed in antigen-presenting cells and are known to participate in peptide presentation to T cells and to be recognized as alloantigens by other T cells. Like some of the HLA-DRB1 alleles, several of these alternate DR molecules have been associated with specific autoimmune diseases and T cell hypersensitivity. Here we present the structure of an HLA-DR molecule (DR52c) containing one of these alternate beta chains (HLA-DRB3*0301) bound to a self-peptide derived from the Tu elongation factor. The molecule shares structurally conserved elements with other MHC class II molecules but has some unique features in the peptide-binding groove. Comparison of the three major HLA-DBR3 alleles (DR52a, b, and c) suggests that they were derived from one another by recombination events that scrambled the four major peptide-binding pockets at peptide positions 1, 4, 6, and 9 but left virtually no polymorphisms elsewhere in the molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.